Published in Drug Week, October 21st, 2005
"The new data indicates Davanat exhibits broad spectrum enhancement of antitumor drugs. Data from the recently finished phase I trial that evaluated advanced patients with a median tumor load of more than 100mm indicates the potential benefit of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.